Search Within

Matthew J Matasar

  1. "Carol Portlock"
  2. "Craig Moskowitz"
  3. "Biostatistics Service"
  4. "Survivorship Research"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (6)
Groups
  1. Biostatistics Service (19)
  2. Center for Hematologic Malignancies (19)
  3. Department of Medicine (19)
  4. Epidemiology and Biostatistics (19)
  5. Hematologic Malignancies, Division of (19)
  6. Lymphoma (19)

More Groups

People
  1. Carol Portlock (19)
  2. Craig Moskowitz (19)
  3. Andrew Zelenetz (18)
  4. Ariela Noy (18)
  5. David Straus (18)
  6. Anas Younes (17)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (8)
  5. 2016 (3)
  6. 2015 (2)

More Years

Publications
  1. Blood (12)
  2. Hematological Oncology (3)
  3. Blood Cancer Journal (2)
  4. Clinical Cancer Research (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
Publishers
  1. American Society of Hematology (12)
  2. Wiley Blackwell (3)
  3. Nature Publishing Group (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Inc. (1)

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse
    Journal Article

    Kumar, A.; Sha, F.; Toure, A.; Dogan, A.; Ni, A.; Batlevi, C. L.; Palomba, M. L. M.; Portlock, C.; Straus, D. J.; Noy, A.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save
  • Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
    Journal Article

    Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
    Blood Cancer Journal (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save